5 results about "Mallotus" patented technology

This invention belongs to the field of pharmaceutical technology and relates to eight glycoside compounds extracted and isolated from the dried leaves of *Picrasma quassioides* Benn, a plant belonging to the genus *Picrasma* in the family Simaroubaceae. The compounds were obtained using chromatographic methods including silica gel chromatography, HP20 column chromatography, ODS column chromatography, and HPLC. This invention also relates to the acetylcholinesterase inhibitory activity of compounds 1-8 and their pharmaceutical uses. The preparation method of this invention is simple, reproducible, and of high purity.

The invention provides an anti-atherosclerosis lipidosome carrier drug and a preparation method thereof, and belongs to the technical field of biological pharmacy, the lipidosome carrier drug is prepared by taking tussah peptide, premna microphylla leaf flavonoid glycoside, clausena lansium leaf polysaccharide and troxerutin as active ingredients. The antheraea pernyi peptide is a product between 1kDa and 5kDa obtained by extracting protein from antheraea pernyi and sequentially carrying out enzymolysis by bacillus subtilis protease and pepsin. The premna microphylla leaf flavonoid glycoside is prepared by performing enzymolysis and water extraction on premna microphylla leaves and then purifying the premna microphylla leaves through an HPD-600 macroporous adsorption resin column. The clausena lansium leaf polysaccharide is prepared by the following steps: extracting clausena lansium leaves with water, precipitating with ethanol, redissolving, and purifying through a DEAE-52 cellulose column and a Sephadex G-100 gel column in sequence. All the components aim at key pathological links of atherosclerosis respectively, and the core advantages of high efficiency, safety and stability are achieved through multi-component synergistic compatibility and closed-loop optimization of a fine preparation process.

The invention belongs to the technical field of biological medicine, and particularly relates to coriaria sinica lactone compounds, a preparation method thereof and application of the coriaria sinica lactone compounds in anti-inflammatory activity. The coriaria sinica lactone compound can significantly inhibit a TLR4 / NF-kappa B signal channel to inhibit downstream inflammatory protein nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and further inhibit inflammatory BV2 cells from generating nitric oxide, the inhibition rate can reach 65.5%, and it is indicated that the coriaria sinica lactone compound has an application prospect in treatment of neuroinflammatory diseases.

The invention belongs to the technical field of traditional Chinese medicines, and provides a traditional Chinese medicine composition for treating hepatic fibrosis, aiming at solving the problems of insufficient curative effect specificity, liver and kidney toxicity and the like in the current treatment of hepatic fibrosis, the traditional Chinese medicine composition for treating hepatic fibrosis comprises the following components in parts by weight: 10 parts of astragalus membranaceus, 10 parts of rhizoma polygonati, 20 parts of mallotus root, 20 parts of turtle shell, 20 parts of salvia miltiorrhiza, 10 parts of codonopsis pilosula, 10 parts of prepared polygonum multiflorum, 13.2 parts of capillary artemisia, 10 parts of rhizoma sparganii, 10 parts of white paeony root and 10 parts of poria cocos. , 8 parts of radix curcumae, 4 parts of endothelium corneum gigeriae galli and 4 According to the traditional Chinese medicine composition disclosed by the invention, through reasonable compounding of the components and optimization of the dosage, the traditional Chinese medicine composition disclosed by the invention can be used for remarkably improving the weight gain and the liver-spleen index of a hepatic fibrosis model mouse, reducing the expression level of inflammatory factors and fibrosis indexes in hepatic tissues and serum, relieving hepatic tissue inflammation infiltration and collagen deposition, and improving the hepatic fibrosis rate. The curative effect on hepatic fibrosis is obvious, and liver and kidney toxicity is avoided.

The invention provides Hainan agar May tea and a preparation method thereof, and relates to the field of herbal tea. The traditional Chinese medicine composition is prepared by mixing the following herbaceous plants: mallotus oblongifolius, phoenix-tail fern, plantain herb, coix leaf, emilia sonchifolia, lygodium japonicum, paphiopedilum armatum, phyllostachys heterocycla, Chinese fevervine herb, tripterygium wilfordii, couch grass root, Newtonian grass, whitebackleaf mallotus root, pteris semipinnata, rhizoma calami, cassia seed, alpinia japonica leaf, water pomegranate leaf, pomegranate leaf, pigeon pea leaf, ficus simplicissima leaf, embelia laeta, flemingia philippinensis leaf, clausena lansium leaf, evodia lepta leaf and honeysuckle. The invention has the following advantages: all the raw materials are selected from deep mountains, dense forests, no pesticide and chemical fertilizer, zero additive and natural taste, the process is innovative: multi-layer drying, stir-frying and airing are carried out, the tea soup is sweet in taste, golden yellow in soup color and rich in aroma level, and the formula is upgraded: special plant resources in Hainan are fully utilized, and various herbaceous plants capable of clearing heat, diminishing inflammation, detoxifying, clearing damp and relieving summer-heat are added, so that the tea has a good health-care effect. And warm herbaceous plants are added, such as phoenix-tail fern, plantain herb, emilia sonchifolia and the like.